Clinicopathological factors for predicting tumor response in hormonal positive/HER2-negative breast cancer patients receiving neoadjuvant chemotherapy

被引：0
|
作者：
Yincharoen, P. [1 ]
Samarnthai, N. [2 ]
Korphaisarn, K. [3 ]
Imruetaicharoenchoke, W. [1 ]
机构：
[1] Mahidol Univ, Fac Med, Div Head Neck & Breast Surg, Dept Surg,Siriraj Hosp, Bangkok, Thailand
[2] Mahidol Univ, Fac Med, Dept Pathol, Siriraj Hosp, Bangkok, Thailand
[3] Mahidol Univ, Siriraj Hosp, Div Med Oncol, Dept Med,Fac Med, Bangkok, Thailand
来源：
BREAST | 2023年 / 68卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P112
引用
收藏
页码：S57 / S57
页数：1
相关论文
共 50 条
  • [31] Luminal subtypes and response to neoadjuvant chemotherapy for hormone receptor-positive HER2-negative patients
    Kadri Altundag
    Breast Cancer Research and Treatment, 2020, 184 : 999 - 999
  • [32] Prognostic Implications of Magee Equation 3 and Residual Cancer Burden in Patients Receiving Neoadjuvant Chemotherapy for Hormone Receptor-Positive HER2-Negative Breast Cancer
    Vazquez, Thais Perez
    Goncalves, Rodrigo
    da Cunha, Juliana Pierobon Gomes
    Rivas, Fernando Wladimir Silva
    Aguiar, Fernando Nalesso
    Baracat, Edmund Chada
    Filassi, Jose Roberto
    MODERN PATHOLOGY, 2025, 38 (06)
  • [33] Neoadjuvant Chemotherapy in Patients with HER2-Negative Breast Cancer: A Report from Clinical Breast Cancer Registry of Iran
    Roudini, Kamran
    Mirzania, Mehrzad
    Yavari, Tahereh
    Seyyedsalehi, Monireh Sadat
    Nahvijou, Azin
    Zebardast, Jayran
    Saadat, Mina
    Khajeh-Mehrizi, Ahmad
    ARCHIVES OF IRANIAN MEDICINE, 2024, 27 (04) : 206 - 215
  • [34] FDG PET/CT during neoadjuvant chemotherapy may predict response in ER-positive/HER2-negative and triple negative, but not in HER2-positive breast cancer
    Koolen, Bas B.
    Pengel, Kenneth E.
    Wesseling, Jelle
    Vogel, Wouter V.
    Peeters, Marie-Jeanne T. F. D. Vrancken
    Vincent, Andrew D.
    Gilhuijs, Kenneth G. A.
    Rodenhuis, Sjoerd
    Rutgers, Emiel J. Th.
    Olmos, Renato A. Valdes
    BREAST, 2013, 22 (05): : 691 - 697
  • [35] FDG PET/CT during neoadjuvant chemotherapy may predict response in ER-positive/HER2-negative and triple negative, but not in HER2-positive breast cancer
    Koolen, B. B.
    Pengel, K. E.
    Wesseling, J.
    Vogel, W. V.
    Peeters, M. T. F. D. Vrancken
    Vincent, A. D.
    Gilhuijs, K. G. A.
    Rodenhuis, S.
    Rutgers, E. J. T.
    Olmos, R. A. Valdes
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2012, 39 : S226 - S226
  • [36] Accessible model predicts response in hormone receptor positive HER2 negative breast cancer receiving neoadjuvant chemotherapy
    Mastrantoni, Luca
    Garufi, Giovanna
    Giordano, Giulia
    Maliziola, Noemi
    Di Monte, Elena
    Arcuri, Giorgia
    Frescura, Valentina
    Rotondi, Angelachiara
    Orlandi, Armando
    Carbognin, Luisa
    Palazzo, Antonella
    Miglietta, Federica
    Pontolillo, Letizia
    Fabi, Alessandra
    Gerratana, Lorenzo
    Pannunzio, Sergio
    Paris, Ida
    Pilotto, Sara
    Marazzi, Fabio
    Franco, Antonio
    Franceschini, Gianluca
    Dieci, Maria Vittoria
    Mazzeo, Roberta
    Puglisi, Fabio
    Guarneri, Valentina
    Milella, Michele
    Scambia, Giovanni
    Giannarelli, Diana
    Tortora, Giampaolo
    Bria, Emilio
    NPJ BREAST CANCER, 2025, 11 (01)
  • [37] The prognostic factors of the HER2-positive breast cancer patients with residual tumor after neoadjuvant chemotherapy
    Tokunaga, Eriko
    Koi, Yumiko
    Ijichi, Hideki
    Koga, Chinami
    Tajiri, Wakako
    Nakamura, Yoshiaki
    Taguchi, Kenichi
    Okamoto, Masahiro
    CANCER SCIENCE, 2022, 113 : 1166 - 1166
  • [38] HER2-positive breast cancer patients receiving trastuzumab treatment obtain prognosis comparable with that of HER2-negative breast cancer patients
    Qin, Tao
    Yuan, Zhongyu
    Peng, Roujun
    Bai, Bing
    Shi, Yanxia
    Teng, Xiaoyu
    Liu, Donggeng
    Wang, Shusen
    ONCOTARGETS AND THERAPY, 2013, 6 : 341 - 347
  • [39] Optimal Choice of Neoadjuvant Chemotherapy for HER2-Negative Breast Cancer: Clinical Insights
    Lucas, Mairi W.
    Kelly, Catherine M.
    CANCER MANAGEMENT AND RESEARCH, 2022, 14 : 2493 - 2506
  • [40] Survival outcomes of neoadjuvant chemotherapy with zoledronic acid for HER2-negative breast cancer
    Ishikawa, Takashi
    Akazawa, Kouhei
    Hasegawa, Yoshie
    Tanino, Hirokazu
    Horiguchi, Jun
    Miura, Daishu
    Hayashi, Mitsuhiro
    Kohno, Norio
    JOURNAL OF SURGICAL RESEARCH, 2017, 220 : 46 - 51
12345